Studying Different Protocols for Prevention of Atonic Postpartum Hemorrhage during Cesarean Delivery in High Risk Group

doi:10.21608/ejhm.2024.393831

Studying Different Protocols for Prevention of Atonic Postpartum Hemorrhage during Cesarean Delivery in High Risk Group

Document Type : Original Article

10.21608/ejhm.2024.393831

Abstract

Background:Various medications and techniques can be used to prevent atonic postpartum hemorrhage (PPH) during Cesarean delivery in high risk women, but optimal protocols remain unclear.
Objective: This work aimed to determine the most effective pharmacological agent for preventing postpartum hemorrhage during Cesarean delivery, while minimizing adverse side effects, particularly in females with a greater risk of atonic PPH. Methods: This randomized double-blind active controlled trial was carried out on pregnant full term > 37 weeks women of high risk group. Patients were divided into four groups: Group 1 (n = 125) who received oxytocin only 20 IU by IV drip over 15- 60 min, group 2 (n = 125) who received oxytocin 20 IU by IV drip over 15- 60 min + misoprostol 600 micrograms orally, group 3 (n = 125) who received carbetocin 100 microgram intravenous in slow rate over one minute, and group 4 (n = 125) who received carbetocin 100 microgram intravenous in slow rate over one minute + misoprostol 600 microgram orally.
Results: Patients who received oxytocin only had a 1.59 higher risk of uterine atony when compared to those who received carbetocin only (95% CI = 1.12 – 2.11, p = 0.001). Meanwhile, patients who did not receive misoprostol had a 1.48 higher risk of uterine atony when compared to those who received misoprostol (95% CI = 1.18 – 1.86, p = 0.001). The incidence of blood transfusion, transfused blood units, intra-operative blood loss, 24-hour estimated post-operative blood loss and total blood loss exhibited a significant difference among the groups (p = 0.020*) with the carbetocin + misoprostol group has the highest values compared to the other groups.
Conclusions: Carbetocin stands out as a reliable uterotonic agent in Cesarean sections, providing effective prevention of postpartum hemorrhage with a favorable side effect profile. Its combination with misoprostol demonstrated promising outcomes, emphasizing its potential for optimizing obstetric care during Cesarean deliveries.

Keywords